CRISPR Therapeutics (CRSP) PT Lowered to $185 at Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Jay Olson lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $185.00 (from $189.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
